Skip to main content
. Author manuscript; available in PMC: 2017 Feb 1.
Published in final edited form as: Gut. 2015 Oct 26;66(2):285–292. doi: 10.1136/gutjnl-2015-309996

Figure 2.

Figure 2

Plots of spectral markers for subjects treated with aspirin or placebo are shown as box plots of per cent changes in spectral slope (SPEC) (A) and fractal dimension (FRAC) (B) values at 3 months post-treatment with aspirin or placebo compared with baseline values, depicting mean (middle line), SD (box) and 95% confidence limits (whiskers). During field carcinogenesis, SPEC typically decreases and FRAC increases, so the data demonstrate a reversion towards less neoplastic signatures by aspirin.